The new season has brought a change in line-up for some companies with new hires and retirements, but for some it meant changing the rules to keep key players.
Metrion has bolstered its drug discovery leadership team, CluePoints has upped its RBM services, and Concept Life Sciences has added to its analytical services division, among other moves this month in the outsourced pharmaceutical services industry.
Insmed has become the first company to receive approval through the limited population pathway for antibacterial and antifungal drugs set up by the US FDA in 2016.
The European Medicines Agency has unearthed a ‘sartan’ medication, in losartan, that contains low levels of the carcinogenic substance, N-nitrosodiethylamine.
Major pharmaceutical companies have defended their accounting and tax policies following the release of an Oxfam report, which claims some of industry’s major players hid profits in overseas tax havens.
The US FDA has issued a warning letter to contract testing laboratory Pharmaceutical Laboratories and Consultants, Inc., after a microbrewery was found to be operating in shared space.
With the US recognising Portugal’s ability to carry out GMP inspections, 15 countries are now part of the mutual recognition agreement between the EU and the US.
Deception among clinical research participants is prevalent and a global issue, say researchers, with self-reported adherence found to be largely inaccurate.
The topic of antimicrobial resistance is back in the spotlight after the US FDA released a new website and a number of proposals to encourage the drug development in the area.
The European Patent Office has upheld protection relating to Gilead’s costly Hepatitis C drug Sovaldi, which Médecins du Monde claims prevents patients from receiving affordable treatment.
Takeda will become the latest company to base its operations within Massachusetts, after announcing it would leave its Deerfield, Illinois headquarters.
The US FDA announced a number of measures it considers as a viable means of combatting AMR, including the idea of hospitals paying a ‘subscription’ to access new medicines.
in-PharmaTechnologist (IPT) speaks to Ettore Cucchetti (EC), CEO of ACGI, about how the biopharma industry is adapting to the threat of counterfeit medicine and how he expects the industry will adopt further measures beyond those stipulated in the EU...
Major pharmaceutical companies and CMOs in the US have announced emergency contingency plans, including facility closures and the relocation of drug products, as Hurricane Florence approaches southeastern shores.
Jiangsu Yew Pharmaceutical outright refused permission for inspectors from Hungary to visit its site, resulting in the suspension of the company’s marketing authorisation.
Three family members charged with producing and supplying unlicensed medicines in the UK used pressing equipment and dyes imported from China, says MHRA.
The top three myths of ‘going digital’ relate to the industry’s self-image, the perceived role of technology, and current market conditions – still, digital is not a fad and is here to stay, says industry expert.
This month marked the effective start date for Parexel's new executive VP and CFO Greg Rush, who joins August's People on the Move with several other c-suite hires, including a new CEO at Citoxlab and COO at ProSciento.
Hu-manity.co is taking on the human data marketplace with its mission to establish a 31st Human Right: Legal ownership of human data as property – a shift that could help improve clinical research and increase transparency, to begin.
The US FDA’s inspection of Lupin gave its manufacturing process for its ‘sartan’ products the all clear but managed to find one “procedural deficiency”.
It has been revealed that the EMA is awarding significantly fewer contracts to evaluate the application of new drugs to the MHRA, as the Brexit deadline nears.
The FDA has announced that a lot of montelukast sodium tablets has been discovered to contain a different type of medicine, potentially posing health risks.
IIVS is collaborating with global laboratories to validate an improved skin sensitization reactivity method to meet toxicology and regulatory requirements.
Deloitte’s acquisition of QSpace expands its IT quality and compliance solutions offering for life sciences firms, including contract research and manufacturing organizations.
The US FDA has rejected Mallinckrodt Pharmaceuticals’ investigational candidate, stannsoporfin, intended for the treatment of newborns at risk of jaundice.
Preparations for an “unlikely” ‘no deal’ Brexit are underway in the UK, with the government instructing pharmaceutical companies to build their medicine reserves before March 2019.
